Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA

Sep. 29, 2015

Video navigation menu

  • T2DM pathogenesis 00:01
  • SGLT2 Inhibitors: How do they work? 06:53
  • Potential pathways to CV benefits of SGLT2-inhibitors based on clinical and mechanistic studies 11:01
  • SGLT2 inhibitors and the kidney 16:20
  • SGLT2 Inhibitors: Risks & Benefits  19:08
  • 2015 ADA-EASD Position Statement on Management of Hyperglycemia in T2DM 22:40